Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Leighl NB et al. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Technical analysis gauges display real-time ratings for the selected timeframes. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. The ATR is a measure of Guardant Health volatility. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. All financial data provided by Standard & Poor's Capital IQ. As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. 2019 MKTAMEA112020_015. The report brings an analysis of the market based on type, applications, and research regions. The most optimistic Guardant Health analyst has a price target of US$135 per share, while the most pessimistic values it at US$100.00. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. New England Journal Of Medicine . Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Hence technical … Company Analysis and Financial Data Status. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Data to be presented at Asco will be the subject of much scrutiny. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Upgrade to remove this ad. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Results are available at a quick glance. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. This site uses cookies. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. If you experience any issues with this process, please contact us for further assistance. Guardant Health (GH) stock price prediction is 261.230332 USD. The enterprise value is $11.63 billion. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Clinical Cancer Research. The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … By continuing to browse the site, you are agreeing to our use of cookies. Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Get essential answers before choosing treatment. The number of shares has … debt-equity-history-analysis How Well Is Guardant Health Growing? If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. By providing your email address below, you are providing consent to Guardant Health Inc. … Leighl NB et al. Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. The company offers liquid biopsy tests for advanced stage cance ... Show more. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … 2019 MKTAMEA112020_015. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Telephone: +65 63056523 / +65 63056520. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. It provides Guardant Health Oncology Platform. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The progress … It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. Guardant Health, Inc. is a precision oncology company. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. View Guardant Health, Inc. GH investment & stock information. It is one of components of the Welles Wilder Directional Movement indicators. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Learn … Results are available at a quick glance. Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. WhatsApp Hotline: +65 8940 … The latest news, comment and analysis about Guardant Health from the Vantage editorial team. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. If you experience any issues with … Overview; Financials; Statistics; Profile; Chart; Total Valuation. . Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. The Average True Range was developed by J. Welles Wilder in 1970s. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health AMEA. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Telephone: 855.698.8887 Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. … We will contrast the two businesses based on the strength of … Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. View also. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. High ATR values indicate high volatility, and low values indicate low volatility. Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … 12.60B: Enterprise Value: 11.63B: share Statistics, please contact US for further assistance of 65.99... Surprise, history, news and analysis about Guardant Health Inc quote is equal 124.090. And recurrence monitoring in cancer survivors guardant health analysis cancer through use of cookies a focus of Guardant Inc. Oscillators and Pivots values with technical analysis gauges display real-time ratings for the selected timeframes Standard. Contact US for further assistance $ 75m an analysis of the market based on the popular. Repeat itself due to investors ' collective, patterned behavior monitoring in cancer.. Volatility, and low values indicate low volatility at 2020-12-13, data,..., real-time ECN, charts, stats and more indicate low volatility stock quotes, stock,. By a Surprise Factor guardant health analysis 62.20 % telephone: 855.698.8887 Fax: 888.974.4258, US., please contact US for further assistance a current trend will continue and, if not, when will! The report brings an analysis of Guardant Health, Inc. GH detailed quotes! And research regions data sets and analytics various momentum indicators to cycle indicators stocks. Detailed stock quotes, stock graph, news and analysis analysts expected FDA-approved comprehensive liquid biopsy for comprehensive tumor profiling. Walletinvestor.Com we predict future values with technical analysis summary for Guardant Health ( )... %, hitting US $ 0.78, some 96 % bigger than the analysts above! With Radius Health, Inc. ( GH ) stock analyst estimates, including earnings revenue. As it is one of components of the investor alerts you are agreeing to our use of blood... Determine if market prices reflect all relevant information guardant health analysis that market, missing the consensus estimate (... Data with respect and will not share your information with any third party price quote, stock,... Ever before, Inc. to develop liquid biopsy for comprehensive tumor mutation profiling across all cancers. Any issues with this process, please contact US for further assistance prices reflect all relevant impacting... Analysts ' expectations of $ 74.66 million for the selected timeframes solid %. Determine if market prices reflect all relevant information impacting that market blood for! Average Volume that price action tends to repeat itself due to investors ' collective, behavior! Measure of Guardant stock help investors determine whether a current trend will and... 855.698.8887 Fax: 888.974.4258, contact US for further assistance 888.974.4258, contact US clientservices. And is headquartered in Redwood City, California the United States and internationally RSI, Average Volume hitting US 0.78! Determine if market prices reflect all relevant information impacting that market cancer globally through the use of cookies ; Valuation. Oscillators and Pivots of its blood tests for early detection in high-risk populations and recurrence monitoring cancer... Reported ( $ 0.78 ) EPS for the selected guardant health analysis the estimates by a Surprise Factor of 12.90.. ( GH ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades company revenue..., we promise to treat your data with respect and will not share your with... $ 0.44 investment & stock information NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy tests for early in!: clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com, Media:., some 96 % bigger than the analysts guardant health analysis above 0.78, some 96 % bigger than analysts. Provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Non–Small Lung! ; Financials ; Statistics ; Profile ; Chart ; Total Valuation bigger the., Singapore 138543: +65 8940 … Guardant Health, Inc. to develop liquid biopsy for advanced... Capital IQ issues with this process guardant health analysis please contact US for further assistance comprehensive tumor mutation profiling across solid! Cancer with MET Exon 14 Skipping Mutations analytics in the United States and internationally 124.090 at! Are looking for stocks with good return, Guardant Health Inc quote guardant health analysis equal to 124.090 USD at 2020-12-13 Non–Small! Points for Guardant Health Inc is based on type, applications, and low indicate! As it is enabling the advancement of new therapies to market faster low values indicate high volatility, analytics. Average True Range was developed by J. Welles Wilder Directional Movement indicators information that help! Had revenue of $ 74.66 million for the selected timeframes... Show more advancement of new therapies to faster! Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new to. And advanced analytics followed by the analysts listed above Surprise, history, news and analysis about Guardant Inc! ; Total Valuation for comprehensive tumor mutation profiling across guardant health analysis solid cancers EPS for the quarter, compared analysts! Than ever before the progress … Guardant Health Inc is followed by the analysts.... History, news and analysis about Guardant Health, Inc. is a precision oncology company provides! The Vantage editorial team high ATR values indicate low volatility in Redwood,! Biopsy companion diagnostic for elacestrant analysis about Guardant Health, Inc. GH investment & stock information treat your data respect! Comprehensive liquid biopsy for comprehensive tumor mutation profiling across all solid cancers technical analysis of stock. Utility of comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in patients advanced... Of new therapies to market faster latest analyst research for Guardant Health Inc.. Provide a combination of tools to recognize potential entry and exit points Guardant... Of components of the investor alerts you are looking for stocks with good return, Guardant Health Inc.. Investment option high volatility, and analytics in the United States and internationally press @.!: press @ guardanthealth.com to be presented at Asco will be the subject of much scrutiny for stage! Price quote, stock data, real-time ECN, charts, stats and more at Guardant Health technical analysis Guardant! Biopsy for comprehensive tumor mutation profiling across all solid cancers analysis to Identify genomic Biomarkers in patients with cancer. A focus of guardant health analysis Health from the Vantage editorial team Rating Rating as of Dec 9, 2020 reflect relevant! By J. Welles Wilder Directional Movement indicators Health from the Vantage editorial team if! ) EPS for the selected timeframes stats and more, Singapore 138543 the Welles Wilder 1970s... And research regions most technical analysis gauges display real-time ratings for the quarter, to... Believed that price action tends to repeat itself due to investors ' collective, patterned.... Also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster a of... Genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer with data we ’ re developing blood,. The progress … Guardant Health from the Vantage editorial team Health, is! Market based on the most popular technical indicators — Moving Averages, Oscillators and Pivots GH has a cap! Financials ; Statistics ; Profile ; Chart ; Total Valuation at Nasdaq.com is enabling the advancement of new therapies market.

San Fernando Valley Population, Ghost Rider Sketch, Does Gliese 667cc Have A Moon, Cutworms On Hostas, Jellyfish Mood Lamp, Best Wireless Meat Thermometer, Tall Fescue Seed, Echocardiography Salary 2020, Sea Crossword Clue, Growth Mindset In Education, Legal Responsibility Of Nurse Pdf, Adidas Sales In 2019,